Bowel cancer trial sees all patients disease-free in huge breakthrough - LADbible
A new bowel cancer trial using immunotherapy (pembrolizumab) before surgery showed 59% of patients cancer-free post-treatment, with all patients remaining cancer-free months later, potentially reducing the need for post-operative chemotherapy.
Reference News
Bowel cancer trial sees all patients disease-free in huge breakthrough - Indy100
All participants in a bowel cancer trial emerged cancer-free after receiving immunotherapy drug pembrolizumab, a significant improvement over standard treatment success rates of less than 5%.
Bowel cancer trial sees all patients disease-free in huge breakthrough - LADbible
A new bowel cancer trial using immunotherapy (pembrolizumab) before surgery showed 59% of patients cancer-free post-treatment, with all patients remaining cancer-free months later, potentially reducing the need for post-operative chemotherapy.